Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Coming soon
- Protocol: GSK219240
- Drug: Belimumab
- Sponsor: GlaxoSmithKline
- Description: A phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosis.
